ABOUT AGO TUMOR

In summary, throughout the last decade probably the most outstanding advantage has long been realized in HER2/neu-overexpressing MBC. Introduction of bevacizumab being a VEGF-directed specific treatment remains a problem on debate. Several of the novel therapeutics on the breast most cancers armamentarium resulted in prolongation of survival for in